BY ASHNA GUPTA: A new Yale study has found a pathway for the secreted protein apelin that could help create new Type 2 diabetes treatments.
Hyung Chun, a cardiology professor at the Yale School of Medicine, found the pathway through which apelin and its receptor — a protein that helps regulate the transfer of fatty acids — control the insulin-glucose relationship in the blood stream. Chun and his lab discovered that one of the main functions in the signaling pathway of apelin is the inhibition of the fatty acid-binding protein 4 (FABP4) within the blood vessels. In this way, the researchers found pathways that could point directly to new therapies of Type 2 diabetes, a disease that has become increasingly prevalent throughout the world. The paper was published in the Science Translational Medicine journal on Sept. 13. (read more)
BY JONAH COMSTOCK: Last week, Centers for Medicare and Medicaid Services Administrator Seema Verma revealed — in a Wall Street Journal editorial and an informal request for information (RFI) — that CMS would be heading in a “new direction” with the Center for Medicare and Medicaid Innovation (CMMI).
Primarily, Verma’s CMS seems interested in dropping the mandatory adoption of new payment methods in favor of a purely voluntary process. Beyond that, the RFI encourages more cost transparency to consumers, more free market competition among providers, and more innovation on the state level.
One area where CMMI and digital health meet is around the National Diabetes Prevention Program (DPP), an evidence-based 12-week course that is on track to become the first preventative service model to be fully reimbursable by Medicare. The program can be delivered in person or digitally, with the latter being offered by companies like Omada Health and Canary Health. (read more)
BY MARY CAFFREY: Dexcom, known to people with diabetes for making continuous glucose monitoring (CGM) systems, has handed a valuable tool to developers of compatible diabetes software with the launch of a public application programming interface, or API.
Release of the API will allow third-party developers to connect with patient-authorized CGM data to create software applications, which Dexcom hopes will drive more digital solutions for payers, providers, and, most critically, people living with the disease.
“In launching this developer platform, Dexcom combines our CGM data expertise with the creativity of the developer ecosystem to enable new solutions and business models in the treatment and management of diabetes,” Annika Jimenez, Dexcom’s senior vice president of data, said in a statement. “Dexcom believes in data mobility and customer choice.” (read more)